Abstract: Provided is a Bacillus subtilis natto strain ST-1008, deposited under the accession number CGMCC No. 17894. Also provided is a method for producing MK-7. The method comprises: culturing the Bacillus subtilis natto strain of CGMCC No. 17894 in a culture medium so as to produce MK-7 in the strain cell and the culture medium, and recovering and purifying MK-7 from the strain cell and the culture medium. Also provided are a MK-7 preparation, a MK-7 pure premix, and a pure MK-7.

Abstract: Disclosed are a strain for producing nattokinase and a production method therefor. In particular, the present invention involves a novel strain capable of producing nattokinase, i.e. Bacillus subtilis natto ST-1086, deposited at the China General Microbiological Culture Collection Center under CGMCC No. 17895. The present invention further involves a method for producing a nattokinase product by means of using the novel strain CGMCC No. 17895 of the present application, wherein the resulting nattokinase product can be used as a drug for dissolving thrombi. The present invention further involves the use of the nattokinase product of the present application for preparing a composition for dissolving thrombi and in a method for treating thrombi.

Abstract: Provided are a method for extracting a hirudin mutant, HV2-Lys47, from a fermentation broth of the hirudin mutant HV2-Lys47 produced by the fermentation of Escherichia coli, and purifying same, the use of the hirudin mutant HV2-Lys47 in an anticoagulated blood collection tube, and an anticoagulated blood collection tube containing the hirudin mutant HV2-Lys47. In the purification method, a membrane technology and a primary column chromatography technology are used to obtain the hirudin mutant HV2-Lys47.

Abstract: Methods, computer program products, NMR assays and automated/semi-automated systems measure concentrations of ionized calcium and/or magnesium or other metabolites in clinical biosamples using NMR data obtained from an NMR spectrometer, such as a clinical NMR Analyzer.

Abstract: A manufacturing-process equipment has a platform assembly, a measurement feedback assembly and a laser-working assembly. The platform assembly has a base and a hybrid-moving platform. The base has a mounting frame. The hybrid-moving platform is mounted on the base and has a long-stroke moving stage and a piezo-driven micro-stage. The long-stroke moving stage has a benchmark set and a driving device. The piezo-driven micro-stage is connected to the long-stroke moving stage and has a working platform. The measurement feedback assembly is securely mounted on the platform assembly and has a laser interferometer, a reflecting device and a signal-receiving device. The laser-working assembly is mounted on the platform assembly, is electrically connected to the measurement feedback assembly and has a laser direct-writing head, a controlling interface device and a positioning interface device.

Abstract: A manufacturing-process equipment has a platform assembly, a measurement feedback assembly and a laser-working assembly. The platform assembly has a base and a hybrid-moving platform. The base has a mounting frame. The hybrid-moving platform is mounted on the base and has a long-stroke moving stage and a piezo-driven micro-stage. The long-stroke moving stage has a benchmark set and a driving device. The piezo-driven micro-stage is connected to the long-stroke moving stage and has a working platform. The measurement feedback assembly is securely mounted on the platform assembly and has a laser interferometer, a reflecting device and a signal-receiving device. The laser-working assembly is mounted on the platform assembly, is electrically connected to the measurement feedback assembly and has a laser direct-writing head, a controlling interface device and a positioning interface device.

Abstract: The present invention relates to a novel compound represented as by formula (I). The present invention also provides a novel strain named as Alternaria alternata var. monosporus, which can produce the compound of formula (I). The inventive strain is cultured in the medium to produce and mass the inventive compound of formula (I) in the strain and the medium. The inventive compound of formula (I) is obtained by recovering and purifying from the mycelia and medium. The compound has strong bioactivity of against cancer, fungi and viruses.

Abstract: There is provided a new strain, i.e. the alternaria alternata var. monosporus ST-026R CGMCC No. 0899, and its use in the production of paclitaxel. The invention also provides a method for the production of paclitaxel by using the strain CGMCC No. 0899.

Abstract: Methods, computer program products, NMR assays and automated/semi-automated systems measure concentrations of ionized calcium and/or magnesium or other metabolites in clinical biosamples using NMR data obtained from an NMR spectrometer, such as a clinical NMR Analyzer.